ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,997.70
0.22%
S&P ASX All Technology
3,259.10
0.24%
Brent Oil
76.80
-0.74%
US Dollar vs AUD
1.48631
0.10%
Bitcoin
60,826.82
2.28%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) News

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:JNJ
DateTimeSourceHeadlineSymbolCompany
15/08/202420:05IH Market NewsGoogle Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
15/08/202420:05IH Market NewsGoogle Forced to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
13/08/202419:43IH Market NewsDell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and MoreNYSE:JNJJohnson and Johnson
10/08/202406:35Edgar (US Regulatory)Form 13F-HR - Quarterly report filed by institutional managers, HoldingsNYSE:JNJJohnson and Johnson
08/08/202407:00PR Newswire (US)Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of MedicineNYSE:JNJJohnson and Johnson
31/07/202411:06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:JNJJohnson and Johnson
31/07/202408:42PR Newswire (US)DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligibleNYSE:JNJJohnson and Johnson
30/07/202420:00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:JNJJohnson and Johnson
30/07/202406:00Business WireJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare ConferenceNYSE:JNJJohnson and Johnson
26/07/202423:38Business WireCourts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step PlanNYSE:JNJJohnson and Johnson
26/07/202423:05Business WireFINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanNYSE:JNJJohnson and Johnson
26/07/202420:07IH Market NewsAlphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in ChinaNYSE:JNJJohnson and Johnson
26/07/202406:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:JNJJohnson and Johnson
24/07/202406:00Business WireJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
23/07/202401:59Business WireLawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanNYSE:JNJJohnson and Johnson
22/07/202422:00PR Newswire (US)Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionNYSE:JNJJohnson and Johnson
17/07/202422:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
17/07/202420:30IH Market NewsTech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory DropNYSE:JNJJohnson and Johnson
17/07/202420:28IH Market NewsSpirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings UpdatesNYSE:JNJJohnson and Johnson
17/07/202420:25Business WireJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024NYSE:JNJJohnson and Johnson
17/07/202420:20Business WireJohnson & Johnson reports Q2 2024 resultsNYSE:JNJJohnson and Johnson
11/07/202421:30Business WireJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26NYSE:JNJJohnson and Johnson
10/07/202407:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
03/07/202422:00PR Newswire (Canada)Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
03/07/202422:00PR Newswire (Canada)Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules pNYSE:JNJJohnson and Johnson
02/07/202421:30PR Newswire (US)CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyNYSE:JNJJohnson and Johnson
29/06/202401:30PR Newswire (US)Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsNYSE:JNJJohnson and Johnson
28/06/202408:46Business WireLawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurdueNYSE:JNJJohnson and Johnson
21/06/202421:30Business WireJohnson & Johnson Completes Acquisition of Proteologix, Inc.NYSE:JNJJohnson and Johnson
21/06/202406:30PR Newswire (US)Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseaseNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Your Recent History

ASX
BHP
BHP
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
NASDAQ
TSLA
Tesla
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
NYSE
MCD
McDonalds
ASX
ORG
Origin Energy
COIN
ADAUSD
Cardano
ASX
NAB
National Australia Bank
ASX
NCM
Newcrest Mining
FX
EURAUD
Euro vs AUD
COIN
SOLUSD
Solana
FX
GBPAUD
Sterling vs AUD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved